IDEAS home Printed from https://ideas.repec.org/a/oup/biomet/v109y2022i2p559-566..html
   My bibliography  Save this article

Multiplicative effect modelling: the general case
[Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer]

Author

Listed:
  • J Yin
  • S Markes
  • T S Richardson
  • L Wang

Abstract

SummaryGeneralized linear models, such as logistic regression, are widely used to model the association between a treatment and a binary outcome as a function of baseline covariates. However, the coefficients of a logistic regression model correspond to log odds ratios, while subject-matter scientists are often interested in relative risks. Although odds ratios are sometimes used to approximate relative risks, this approximation is appropriate only when the outcome of interest is rare for all levels of the covariates. Poisson regressions do measure multiplicative treatment effects including relative risks, but with a binary outcome not all combinations of parameters lead to fitted means that are between zero and one. Enforcing this constraint makes the parameters variation dependent, which is undesirable for modelling, estimation and computation. Focusing on the special case where the treatment is also binary, Richardson et al. (2017) proposed a novel binomial regression model that allows direct modelling of the relative risk. The model uses a log odds product nuisance model leading to variation-independent parameter spaces. Building on this we present general approaches to modelling the multiplicative effect of a continuous or categorical treatment on a binary outcome. Monte Carlo simulations demonstrate the desirable performance of our proposed methods. An analysis of the relationship between passenger class and survival for passengers on the Titanic further exemplifies our methods.

Suggested Citation

  • J Yin & S Markes & T S Richardson & L Wang, 2022. "Multiplicative effect modelling: the general case [Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer]," Biometrika, Biometrika Trust, vol. 109(2), pages 559-566.
  • Handle: RePEc:oup:biomet:v:109:y:2022:i:2:p:559-566.
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1093/biomet/asab064
    Download Restriction: Access to full text is restricted to subscribers.
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:oup:biomet:v:109:y:2022:i:2:p:559-566.. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Oxford University Press (email available below). General contact details of provider: https://academic.oup.com/biomet .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.